Inactive Instrument

Pieris Pharmaceuticals

Stocks

PIRS

US7207952026

Pieris Pharmaceuticals, Inc. announced that it has received funding

Published on 08/06/2024

S&P Capital IQ

Add MarketScreener to your sources

PIERIS PHARMACEUTICALS

-5.10%

Pieris Pharmaceuticals, Inc. announced that it has entered into a Subscription and Investment Representation Agreement with an individual investor, James Geraghty, pursuant to which the Company issued and sold one share of the Company?s Series F Preferred Stock, par value $0.001 per share to the Purchaser for $1 cash on August 7, 2024.

Add MarketScreener to your sources

Latest news about Pieris Pharmaceuticals

12/12/24	Palvella Therapeutics, Inc.(NasdaqCM:PIRS) dropped from NASDAQ Composite Index	CI
12/12/24	Palvella Therapeutics, Inc. completed the acquisition of Pieris Pharmaceuticals, Inc. in a reverse merger transaction.	CI
13/11/24	Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
07/11/24	Pieris Pharmaceuticals' Merger Target Palvella Doses First Patient in Phase 3 Trial of Lymphatic Drug	MT
14/08/24	Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
06/08/24	Pieris Pharmaceuticals, Inc. announced that it has received funding	CI
24/07/24	Top Midday Gainers	MT
24/07/24	Pieris Pharmaceuticals, Palvella Therapeutics Agree to Merge; Pieris Shares Jump	MT
24/07/24	Traders Digest Alphabet, Tesla Results, Fueling Premarket Losses for US Equity Futures	MT
24/07/24	Palvella Therapeutics, Inc., Pieris Pharmaceuticals, Inc. - M&A Call
24/07/24	Top Premarket Gainers	MT
24/07/24	Pieris Pharmaceuticals, Inc. Announces Stepping Down of Shane Olwill as Senior Vice President and Chief Development Officer	CI
24/07/24	Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. Announce Definitive Merger Agreement	CI
23/07/24	Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. in a reverse merger transaction.	CI
03/07/24	Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH, es Laboratoires Servier and Institut de Recherches Internationales Servier Announce Termination of A Material Definitive Agreement	CI

Chart Pieris Pharmaceuticals

Duration

Period

PIRS: Dynamic Chart

Company Profile

Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Companyâ€™s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.

Employees

Sector

More about the company